Literature DB >> 10458224

Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.

L Esserman1, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles.   

Abstract

PURPOSE: The staging and treatment for breast cancer are changing; there is an increase in the incidence of ductal carcinoma-in-situ, the use of fine-needle aspiration and stereotactic biopsy for diagnosis, and the use of neoadjuvant chemotherapy. Thus, there is a need for a tool to assess more precisely the extent of cancer in the breast before surgery. To better plan surgical and chemotherapeutic interventions, we evaluated high-resolution magnetic resonance imaging (MRI) as such a tool. PATIENTS AND METHODS: Fifty-seven patients with 58 cases of breast cancer were evaluated preoperatively with MRI using a technique called the triple-acquisition rapid gradient echo technique to maximize anatomic detail. Imaging results were compared with mammography and subsequent pathology results.
RESULTS: Magnetic resonance imaging correctly identified residual or primary cancer in 55 of 58 cases and accurately predicted the extent of the cancer in 54 of 58 cases. The anatomic extent was more accurately defined with MRI compared with mammography (98% v 55%). Magnetic resonance imaging added the greatest value in cases of multifocal disease.
CONCLUSION: By applying MRI selectively to patients with a known diagnosis of cancer and focusing on defining the extent of malignant lesions, we were able to obtain clear and accurate anatomic information. Our results suggest that MRI could provide very valuable information for preoperative planning and single-stage resection in breast cancer. Based on preliminary data from our series, MRI would be valuable as a staging tool in the preoperative setting even if the cost is in the range of $1,300 to $2,000. It is already significantly less than the target cost, so it is reasonable to refine this technique for clinical use to help plan the most appropriate surgical intervention and possibly reduce costs as well. A careful prospective study is warranted to validate our findings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458224     DOI: 10.1200/JCO.1999.17.1.110

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  79 in total

Review 1.  Integration of breast imaging into cancer management.

Authors:  L J Esserman; D Wolverton; N Hylton
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  Incremental value of magnetic resonance imaging for breast surgery planning.

Authors:  Sibel Ozkan Gurdal; Beyza Ozcinar; Munire Kayahan; Abdullah Igci; Mehtap Tunaci; Vahit Ozmen; Gulden Acunas; Ekrem Yavuz; Mustafa Kecer; Mahmut Muslumanoglu
Journal:  Surg Today       Date:  2013-01       Impact factor: 2.549

3.  Diffusion-weighted magnetic resonance imaging in focal breast lesions: analysis of 78 cases with pathological correlation.

Authors:  F Fornasa; L Pinali; A Gasparini; E Toniolli; S Montemezzi
Journal:  Radiol Med       Date:  2010-10-06       Impact factor: 3.469

4.  Emerging Breast Imaging Technologies on the Horizon.

Authors:  Srinivasan Vedantham; Andrew Karellas
Journal:  Semin Ultrasound CT MR       Date:  2017-09-13       Impact factor: 1.875

5.  Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.

Authors:  Filippo Montemurro; Laura Martincich; Giovanni De Rosa; Stefano Cirillo; Vincenzo Marra; Nicoletta Biglia; Marco Gatti; Piero Sismondi; Massimo Aglietta; Daniele Regge
Journal:  Eur Radiol       Date:  2005-01-27       Impact factor: 5.315

6.  Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.

Authors:  Anjali S Kumar; Daniel F Chen; Alfred Au; Yunn-Yi Chen; Jessica Leung; Elisabeth R Garwood; Jessica Gibbs; Nola Hylton; Laura J Esserman
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

7.  Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients.

Authors:  Eline E Deurloo; William F A Klein Zeggelink; H Jelle Teertstra; Johannes L Peterse; Emiel J Th Rutgers; Sara H Muller; Harry Bartelink; Kenneth G A Gilhuijs
Journal:  Eur Radiol       Date:  2005-11-19       Impact factor: 5.315

8.  Assessment of tumor morphology on diffusion-weighted (DWI) breast MRI: Diagnostic value of reduced field of view DWI.

Authors:  Maarten W Barentsz; Valentina Taviani; Jung M Chang; Debra M Ikeda; Kanae K Miyake; Suchandrima Banerjee; Maurice A A J van den Bosch; Brian A Hargreaves; Bruce L Daniel
Journal:  J Magn Reson Imaging       Date:  2015-04-24       Impact factor: 4.813

9.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

10.  The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer.

Authors:  Uwe Fischer; Olivier Zachariae; Friedemann Baum; Dorit von Heyden; Matthias Funke; Torsten Liersch
Journal:  Eur Radiol       Date:  2004-07-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.